In addition to MLH1, MSH2, MSH6, PMS2, and EPCAM mutations, screening for MLH3, MSH3, and PMS1 mutations may benefit newly diagnosed endometrial carcinoma patients [32]. Here, MSH2 is linked to endometrial carcinoma.